title: The Impact of Diabetes on Gynecologic Cancer: Current Status and Future Directions.
abstract: Diabetes mellitus has reached epidemic proportions in both the United States and worldwide with most authorities reporting a doubling in the prevalence of diabetes over the last 20-30 years. While this epidemic is closely tied to obesity, diabetes mellitus presents potential clinical challenges over and above that observed with obesity alone. From a women's health care prospective, this rise in diabetes may impact a woman's health across her lifespan. More specifically, diabetes impacts not only pregnancy as well as well as other medical conditions, but increases the risk for the development of various malignancies. From a gynecologic cancer standpoint, diabetes is most closely associated with endometrial adenocarcinomas, although increasing attention is being placed upon diabetes and ovarian cancer. Attention is also being placed on the potential role of metformin and its impact on outcomes in diabetics with cancer, as well as a potential preventative and/or adjunctive therapy for gynecologic cancer.
authors.affiliation: Department of Obstetrics and Gynecology, University of Alabama at Birmingham.
authors.forename: Brittany
authors.initials: B
authors.lastname: Lees
authors.affiliation: Division of Gynecologic Oncology, University of Alabama at Birmingham, 619 19 Street South, Room 10250, Birmingham, Alabama 35249, .
authors.forename: Charles A
authors.initials: CA
authors.lastname: Leath
keywords: Diabetes mellitus; Gynecologic cancer; Metformin; Ovarian Cancer; Review; Uterine cancer
references.citation: Clin Cancer Res. 2013 Nov 15;19(22):6074-83
references.pmid: 23958744
references.citation: Cancer Prev Res (Phila). 2012 Jul;5(7):901-10
references.pmid: 22609763
references.citation: Endocrine. 2014 Feb;45(1):28-36
references.pmid: 23640372
references.citation: Oncol Rep. 2015 Feb;33(2):744-50
references.pmid: 25421433
references.citation: Asian Pac J Cancer Prev. 2014;15(23):10067-70
references.pmid: 25556427
references.citation: Gynecol Oncol. 2014 Jan;132(1):236-40
references.pmid: 24189334
references.citation: Int J Gynecol Cancer. 2011 Dec;21(9):1525-32
references.pmid: 22080892
references.citation: Obstet Gynecol Surv. 2014 Aug;69(8):477-89
references.pmid: 25144611
references.citation: Diabetes Care. 2012 Feb;35(2):299-304
references.pmid: 22266734
references.citation: Gynecol Oncol. 2013 Jul;130(1):12-8
references.pmid: 23578540
references.citation: Ann Oncol. 2011 Jun;22(6):1332-8
references.pmid: 21131370
references.citation: Eur J Cancer. 2007 Mar;43(4):690-709
references.pmid: 17223544
references.citation: Int J Gynecol Cancer. 2013 Mar;23(3):402-12
references.pmid: 23354371
references.citation: Maturitas. 2013 Jan;74(1):37-43
references.pmid: 23153683
references.citation: Gynecol Oncol. 2014 Dec;135(3):614-21
references.pmid: 25455733
references.citation: Biomed Res Int. 2015;2015:920618
references.pmid: 25866823
references.citation: Cancer. 2014 Oct 1;120(19):2986-95
references.pmid: 24917306
references.citation: N Engl J Med. 1996 Feb 29;334(9):574-9
references.pmid: 8569826
references.citation: Obstet Gynecol. 2012 Jan;119(1):61-7
references.pmid: 22183212
references.citation: Int J Epidemiol. 2015 Aug;44(4):1353-63
references.pmid: 25652574
references.citation: Nat Rev Endocrinol. 2011 Nov 08;8(4):228-36
references.pmid: 22064493
references.citation: Gynecol Oncol. 2014 Nov;135(2):273-7
references.pmid: 25220626
references.citation: BMJ Open Diabetes Res Care. 2015 Jan 24;3(1):e000049
references.pmid: 25664181
references.citation: Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):98-107
references.pmid: 15668482
references.citation: CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
references.pmid: 25559415
references.citation: J Clin Oncol. 2015 May 1;33(13):1460-6
references.pmid: 25800756
references.citation: Front Biosci. 2003 May 01;8:d714-22
references.pmid: 12700030
references.citation: Int J Cancer. 2015 Aug 15;137(4):903-10
references.pmid: 25604005
references.citation: Am J Obstet Gynecol. 2015 Apr;212(4):479.e1-479.e10
references.pmid: 25446664
references.citation: Diabetologia. 2007 Jul;50(7):1365-74
references.pmid: 17476474
references.citation: Gynecol Oncol. 2011 Nov;123(2):200-4
references.pmid: 21802715
references.citation: Br J Cancer. 2013 Aug 6;109(3):751-5
references.pmid: 23860524
references.citation: PLoS Med. 2012;9(4):e1001200
references.pmid: 22606070
references.citation: Lancet Diabetes Endocrinol. 2014 Jan;2(1):56-64
references.pmid: 24622669
references.citation: Br J Cancer. 2015 Sep 1;113(5):817-26
references.pmid: 26151456
references.citation: J Natl Compr Canc Netw. 2013 Oct 1;11(10):1199-209
references.pmid: 24142821
references.citation: BMJ. 2005 Jun 4;330(7503):1304-5
references.pmid: 15849206
references.citation: Trends Endocrinol Metab. 2013 Sep;24(9):469-80
references.pmid: 23773243
references.citation: Gynecol Oncol. 2012 May;125(2):458-69
references.pmid: 22252099
references.citation: Gynecol Oncol. 2011 Apr;121(1):106-11
references.pmid: 21236474
references.citation: Br J Cancer. 2014 Sep 23;111(7):1432-9
references.pmid: 25051408
references.citation: Gynecol Oncol. 2015 Feb;136(2):341-7
references.pmid: 25499603
references.citation: Cancer. 2013 Feb 1;119(3):555-62
references.pmid: 23208739
references.citation: Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):261-7
references.pmid: 25587111
references.citation: Gynecol Oncol. 2010 Jan;116(1):92-8
references.pmid: 19822355